Stocks · News reference
Hiteck grants Visara, a majority-owned ophthalmology subsidiary of NovaBridge Biosciences (NASDAQ:NBP), exclusive worldwide rights, excluding Greater China, to develop and commercialize HT006.2.2Hiteck retains all
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Visara secures exclusive worldwide rights, excluding Greater China, from Wuhan Hiteck Biological Pharma to develop and commercialize HT006.2.2Visara plans to develop HT006.2.2 as VIS-102, its second clinical-stage
NovaBridge Biosciences (NASDAQ:NBP) held its quarterly earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data and